Immediate results of intranasal administrations of multipotent mesenchymal stromal cells (MMSC) to Parkinson's disease (PD) patients

Introduction PD is a steadily progressive neurodegenerative disease. MMSC administration is considered one of the most promising therapies to modify the course of the disease. Objective Assessment of the immediate results of intranasal transplantation of autologous MMSC on motor symptoms of patients with PD. Materials and methods Four patients with PD were subjected to cell transplantation (all males; age = 42,7 ± 8,3 SD). Neurological examination was carried out in the morning after a 12 or (24) - hour break in taking anti-Parkinsonian drugs («OFF-state»), and one hour after the drugs were taken («ON-state»). The intensity of motor symptoms was assessed using the third part of the Unified Parkinson's disease Rating Scale (UPDRS) of the International Society for Movement Disorders. Initial assessment was performed 1 day before the transplantation, and the progress was measured one week after the procedure. Non-parametric methods of statistical analysis were used. The study was approved by local ethics committee. All subjects signed informed consent form before participating in the study. Results An improvement was detected in all the patients. Before the transplantation median levels of UPDRS in «OFF»-state was 33.4 [28.7; 39.2], and in «ON»-28.9 [21.2; 34.9]. After the procedure - «Off»-period was 31.1 [26.4; 36.5], «ON»-26.2 [19.4; 31.4]. Conclusion Transplantation of MMSC is a promising therapeutic intervention in treatment of PD that could influence the symptoms, and potentially the pathogenesis, of the disease. However, further examination is needed to estimate the consequences of this complex and insufficiently explored method.